Novo Nordisk Foundation CEO surprised by mRNA Nobel Prize snub

The social significance of the mRNA-based Covid-19 vaccines is obvious, says Mads Krogsgaard Thomsen, who suggests that the technology may not have won because the committee did not manage to evaluate the vaccines in time.
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen | Photo: Jacob Ehrbahn/Politiken
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen | Photo: Jacob Ehrbahn/Politiken
by ulrich quistgaard, translated by catherine brett

The CEO of the Novo Nordisk Foundation, Mads Krogsgaard Thomsen, believes that David Julius and Ardem Patapoutian only won the Nobel Prize for medicine because the committee did not have time to properly evaluate the research behind the mRNA-based Covid-19 vaccines.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading